Press Room

The Biden Cancer Moonshot announced today the expansion of coverage for patient navigation services in plans from seven health insurance companies.

WASHINGTON, D.C.— March 7, 2024 —Ahead of  President Biden’s State of the Union Address, the American Cancer Society Cancer Action Network (ACS CAN) is calling on the president to emphasize the need for continued bipartisan support for increased federal investment for cancer research at the National Institutes of Health (NIH) and National Cancer Institute (NCI) as well as prevention program funding at the Centers for Disease Control and Prevention (CDC). Additionally, ACS CAN is urging the president to finalize the Food and Drug Administration’s rule prohibiting the sale of menthol in cigarettes without delay. 

Milwaukee attorney Philip R. O’Brien has accepted the role of Cancer Votes National Ambassador for the American Cancer Society Cancer Action Network (ACS CAN), the advocacy affiliate of the American Cancer Society (ACS). This role is an expansion of O’Brien’s current commitment to ACS CAN as a member of its national Board of Directors since 2019. Cancer Votes is ACS CAN’s nonpartisan electoral program, a public education avenue through which cancer issues are elevated as a key priority during election cycles. As National Ambassador, Phil O’Brien will serve as a brand leader, seeking to draw high levels of engagement from volunteers, the media and the advocacy and business communities.

Today, the U.S. Court of Appeals for the Fifth Circuit will hear oral arguments in Braidwood Management v. Becerra, a case that threatens access to evidence-based preventive services without cost-sharing as required under the Affordable Care Act (ACA). The services at-risk include those recommended by scientific experts at the U.S. Preventive Services Task Force (USPSTF), the Advisory Committee on Immunization Practices (ACIP) and the Health Resources and Services Administration (HRSA). 

A new paper released today in the Journal of Clinical Oncology finds that while incorporating pharmacogenomic (PGx) testing into cancer care can help improve patient outcomes, barriers to PGx testing, discovery, and implementation are impacting its adoption and creating disparities that impact diverse populations.

Protecting free preventive cancer screenings and reducing the burden of medical debt are the top issues of concern for cancer patients and survivors today, according to a new survey by the American Cancer Society Cancer Action Network (ACS CAN) that asked participants to select their leading policy priorities for the year. 

Dr. Christina Annunziata, the Senior Vice President of Extramural Discovery Science at the American Cancer Society, testified today before the House Committee on Energy and Commerce’s Subcommittee on Health in support of the Screening for Communities to Receive Early and Equitable Needed Services (SCREENS) for Cancer Act and the Women and Lung Research and Preventive Services Act.

Today, the American Cancer Society Cancer Action Network (ACS CAN) issued a letter to the National Institutes of Standards and Technology (NIST) commenting on the utilization of march-in rights (MIR) to lower prescription drug costs following the release of new guidance by the administration on its application.  

On the two-year anniversary of the reignited Cancer Moonshot, the American Cancer Society Cancer Action Network (ACS CAN) is calling on the White House and Congress to reinforce their commitment to end cancer as we know it by taking key steps to prioritize cancer prevention and research.

WASHINGTON, D.C. – Today, the American Cancer Society Cancer Action Network (ACS CAN) was joined by 20 other organizations in proposing the Health and Human Services Office of Inspector General adopt a new regulatory safe harbor from the Anti-kickback Statute that would allow cli